Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience

Biosimilars offer cost-effective and safe treatment options both for patients and healthcare systems. CT-P10 is the first biosimilar of rituximab approved in Europe for use in all indications of originator rituximab (oRTX). This study aimed to provide real-life data on treatment changes and adverse...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahap-Kara, Melda, Duran, Emine, Bayraktar-Ekincioglu, Aygin, Karadag, Omer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Im - Original
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951838/
https://www.ncbi.nlm.nih.gov/pubmed/36826744
http://dx.doi.org/10.1007/s11739-023-03222-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951838/
https://www.ncbi.nlm.nih.gov/pubmed/36826744
http://dx.doi.org/10.1007/s11739-023-03222-x

Ejemplares similares